Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL11: Obinutuzumab + Chlorambucil vs Rituximab + Chlorambucil vs Chlorambucil in CLL
NCT02053610Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2009
- Primary completion
- Aug 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Roche. Started Dec 2009; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02053610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053610.